Abstract:Background: Aspirin is a frequently prescribed drug for primary and secondary prevention of myocardial infarction, stroke and cardiovascular death. However, aspirin resistance may affect up to 45% of the population. Little is known on the role of genetic factors that contribute to resistance or augmented response to aspirin in different human populations. Methods: In a large sample of nonsmoker, medication-free healthy volunteers from mainland China (n = 323; age: 22.1 +/- 2.0 years) (mean standard deviation), we determined the frequency of polymorphisms in cyclooxygenase 1 (COX1) (A-842G and C50T), glycoprotein IIIa (GPIIIa) (PLA1/A2) and purinergic receptor P2Y (P2Y1) (C893T and A1622G) genes. These candidate genes were chosen on the basis of their impact on platelet physiology and aspirin mode of action. A four panel P2Y1 genotype-stratified sample of healthy volunteers (n = 24 in total), identified from the large study sample above, prospectively received a 100 mg daily oral dose of aspirin for 7 days. We measured changes in platelet aggregation before and after aspirin treatment. As a comparison reference group, 6 out of 24 subjects in the prospective aspirin trial had the P2Y1 CT893/AG1622 genotype that displays a low frequency (< 7%) in the Chinese population. Results: COX1 A-842G, C50T and GPIIIa PLAVA2 genetic polymorphisms were not observed in our sample from mainland China. Allele frequencies of P2Y1 893T and 1622G were 3.5 and 30.6%, respectively. The heterozygosity for the P2YI A1622G polymorphism observed in the present study was different to Caucasians; Chinese displayed a higher allele frequency for the 1622G allele. After aspirin treatment, the net decrease in arachiclonic acid-induced platelet aggregation was significantly larger in the P2Y1 CT893/AG1622 genotype panel (83.4 +/- 3.7%, net reduction by aspirin expressed as percentage of baseline) compared with CC893/GG1622 (68.2 +/- 13.5%), CC893/AG1622 (68.9 +/- 9.6%) and CC893/AA1622 (65.1 +/- 9.1 %) genotypic groups (p = 0.012, 0.025 and 0.004, respectively; statistical power = 77%). There was no significant difference in antiplatelet effect of aspirin among the CC893/GG1622, CC893/AG1622 and CC893/AA1622 genotypes (p > 0.05). Conclusions: The COX1 A-842G, C50T and GPIIIa PLAVA2 polymorphisms are rare in Chinese. In contrast to previous studies in Caucasian populations, these candidate functional polymorphisms are unlikely to be significant contributors to aspirin pharmacodynamics in Chinese persons. Importantly, the presence of the P2YI 893CC genotype appears to confer an attenuated antiplatelet effect during aspirin treatment in healthy Chinese volunteers. These data collectively underscore the importance of population-to-population variability in clinical pharmacogenetics research and provide a basis for further long-term studies of aspirin response and P2Y1 genetic variation in patients with cardiovascular risk.

P2RY1 and P2RY12 Polymorphisms and On‐aspirin Platelet Reactivity in Patients with Coronary Artery Disease

Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.

Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin.

Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease

The Correlation Between Aspirin Resistance and P2Y1 Gene Polymorphism in Patients with Cardiovascular or Cerebrovascular Diseases

Candidate Gene and Pathway Analyses Identifying Genetic Variations Associated with Prasugrel Pharmacokinetics and Pharmacodynamics.

Predictors of High On-Aspirin Platelet Reactivity in Elderly Patients with Coronary Artery Disease

Association Between P2RY12 Gene Polymorphisms and Adverse Clinical Events in Coronary Artery Disease Patients Treated with Clopidogrel: A Systematic Review and Meta-Analysis.

Genetic factors related to aspirin resistance using the Multiplate® device in Hong Kong Chinese patients with stable coronary heart disease

A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel

Aspirin Resistance: Clinical Significance and Genetic Polymorphism

Associations of P 2 Y 12 R Gene Polymorphisms with Susceptibility to Coronary Heart Disease and Clinical Efficacy of Antiplatelet Treatment with Clopidogrel Running title : Associations of SNPs in the P 2 Y 12 R gene with CHD

Haplotype of Platelet Receptor P2RY12 Gene is Associated with Residual Clopidogrel On-Treatment Platelet Reactivity

Influence Of P2y12 Polymorphisms On Platelet Activity But Not Ex-Vivo Antiplatelet Effect Of Ticagrelor In Healthy Chinese Male Subjects

Clopidogrel‐associated Genetic Variants on Inhibition of Platelet Activity and Clinical Outcome for Acute Coronary Syndrome Patients

Relationship Between Clopidogrel-Related Polymorphisms and Variable Platelet Reactivity at 1 Year: A Cohort Study from Han Chinese.

Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome

The impact of PEAR1 gene polymorphisms on outcomes of acute coronary syndrome patients

Multi-parameter Assessment of Platelet Inhibition and Its Stability During Aspirin and Clopidogrel Therapy

Genetic Mutations in PEAR1 Associated with Cardiovascular Outcomes in Chinese Patients with Acute Coronary Syndrome

Advances and Perspectives in methods for identifying high platelet reactivity